31 October 2019
Visiongain has launched a new pharma report Attention Deficit Hyperactivity Disorder Drugs Market: Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy.
The global attention deficit hyperactivity disorder is anticipated to witness strong growth during the forecast period. Factors such as the growing prevalence of the ADHD cases in adults and children, growing awareness coupled with support from the government as well as rising regulatory approvals will drive market growth.
The lead analyst of the report commented "The global attention deficit disorder market is one that is driven by innovation. This is vital for maintaining the rich pipeline of ADHD drugs seen in the market today. There is increasing focus to identify and treat ADHD that currently are undertreated and try to serve these neglected markets. This creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market. This prevents stagnation within the market and will help drive the growth of attention deficit disorder market."
Leading companies featured in the report include Eli Lilly, Johnson and Johnson, Lupin Limited, Mallinckrodt & Co., Neos Therapeutics, Pfizer Inc., Purdue Pharma L.P., Takeda Pharmaceuticals and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
06 April 2021
Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.
01 April 2021
Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.